Payers, providers, patients and pharmaceutical companies are all interested in understanding the value of specific treatments protocols, whether these rely on medications, medical devices or other treatment modalities.  Additionally, there are different axes on which value can be measured, starting with traditionally defined clinical endpoints, but increasingly relying on genomic, financial and patient experience endpoints.

The problem is that the ability to compile large robust datasets of deep phenotypic and genotypic information, supplemented by financial and patient reported outcome (PRO) data does not exist on a national or global basis.  While there are numerous registries collecting increasing amounts of deep clinical data, these are very manually intensive and rarely connected to other data sources.

The solution is what our experts refer to as the registry of the future.  A registry that leverages the large quantities of data available and innovative technology to provide the real world evidence required to answer the questions asked by multiple stakeholders.